• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu


3/10/2008 Telecon - Rotarix


DATE: March 10, 2008, 11:00 AM
FROM: Laraine S. Henchal, Microbiologist Reveiwer, DVRPA, CBER, Review Committee Chair, STN 125265/0
SUBJECT: Telecon in regard to inclusion/exclusion of Neisseria meningitidis assay data from review for BLA for Rotarix®

I received a call from Milan Blake and Chris Lynch in regard to the necessity for inclusion of Chris's review of the Neisseria meningitidis assay data in the BLA. Since the co-administration of other vaccines study 060 is considered by CBER to be the pivotal co-administration study, and no Neisseria vaccine was administered in that study, we all agreed that it was not necessary to include the assay review in the file.

CBER participants:

Laraine Henchal
Christian Lynch
Milan Blake


Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002